| Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation B Kaufman, R Shapira-Frommer, RK Schmutzler, MW Audeh, ... Journal of clinical oncology 33 (3), 244, 2015 | 1314 | 2015 |
| Ribociclib as first-line therapy for HR-positive, advanced breast cancer GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... New England journal of medicine 375 (18), 1738-1748, 2016 | 1022 | 2016 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 694 | 2017 |
| Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer … R Herrmann, G Bodoky, T Ruhstaller, B Glimelius, E Bajetta, J Schuller, ... Journal of Clinical Oncology 25 (16), 2212-2217, 2007 | 662 | 2007 |
| Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases F Saad, JE Brown, C Van Poznak, T Ibrahim, SM Stemmer, AT Stopeck, ... Annals of Oncology 23 (5), 1341-1347, 2012 | 656 | 2012 |
| Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood … EJ Shpall, RB Jones, SI Bearman, WA Franklin, PG Archer, T Curiel, ... Journal of Clinical Oncology 12 (1), 28-36, 1994 | 453 | 1994 |
| Randomized phase II study of the anti–epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple … J Baselga, P Gómez, R Greil, S Braga, MA Climent, AM Wardley, ... Journal of clinical oncology 31 (20), 2586, 2013 | 346 | 2013 |
| The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy R Scherz-Shouval, S Santagata, ML Mendillo, LM Sholl, I Ben-Aharon, ... Cell 158 (3), 564-578, 2014 | 256 | 2014 |
| Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced … GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, ... Annals of Oncology 29 (7), 1541-1547, 2018 | 254 | 2018 |
| Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials L Bonilla, I Ben-Aharon, L Vidal, A Gafter-Gvili, L Leibovici, SM Stemmer Journal of the National Cancer Institute 102 (24), 1845-1854, 2010 | 214 | 2010 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 188 | 2017 |
| Interventions for alleviating cancer-related dyspnea: a systematic review I Ben-Aharon, A Gafter-Gvili, M Paul, L Leibovici, SM Stemmer Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2008 | 181 | 2008 |
| Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy SM Domchek, C Aghajanian, R Shapira-Frommer, RK Schmutzler, ... Gynecologic oncology 140 (2), 199-203, 2016 | 174 | 2016 |
| Actual and preferred place of death of home-dwelling patients in four European countries: making sense of quality indicators ML De Roo, G Miccinesi, BD Onwuteaka-Philipsen, N Van Den Noortgate, ... PloS one 9 (4), e93762, 2014 | 134 | 2014 |
| The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-κB signal transduction pathways S Bar-Yehuda, SM Stemmer, L Madi, D Castel, A Ochaion, S Cohen, ... International journal of oncology 33 (2), 287-295, 2008 | 134 | 2008 |
| White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. MS Brown, SM Stemmer, JH Simon, JC Stears, RB Jones, PJ Cagnoni, ... American Journal of Neuroradiology 19 (2), 217-221, 1998 | 131 | 1998 |
| Doxorubicin-induced ovarian toxicity I Ben-Aharon, H Bar-Joseph, G Tzarfaty, L Kuchinsky, S Rizel, ... Reproductive Biology and Endocrinology 8 (1), 1-7, 2010 | 130 | 2010 |
| Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter … J Bernhard, D Dietrich, W Scheithauer, D Gerber, G Bodoky, T Ruhstaller, ... Journal of clinical oncology 26 (22), 3695-3701, 2008 | 126 | 2008 |
| Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, ... Annals of Oncology 27 (3), 417-423, 2016 | 125 | 2016 |
| A prospective cohort study of the effects of adjuvant breast cancer chemotherapy on taste function, food liking, appetite and associated nutritional outcomes A Boltong, S Aranda, R Keast, R Wynne, PA Francis, J Chirgwin, K Gough PloS one 9 (7), e103512, 2014 | 106 | 2014 |
